GSK
Price
$37.58
Change
+$0.83 (+2.26%)
Updated
Aug 7, 04:37 PM (EDT)
Capitalization
88.13B
83 days until earnings call
JNJ
Price
$171.55
Change
+$0.96 (+0.56%)
Updated
Aug 7, 04:59 PM (EDT)
Capitalization
380.22B
75 days until earnings call
Interact to see
Advertisement

GSK vs JNJ

Header iconGSK vs JNJ Comparison
Open Charts GSK vs JNJBanner chart's image
GSK
Price$37.58
Change+$0.83 (+2.26%)
Volume$5.22K
Capitalization88.13B
Johnson & Johnson
Price$171.55
Change+$0.96 (+0.56%)
Volume$46.19K
Capitalization380.22B
GSK vs JNJ Comparison Chart in %
Loading...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GSK vs. JNJ commentary
Aug 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Buy and JNJ is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 07, 2025
Stock price -- (GSK: $36.75 vs. JNJ: $170.59)
Brand notoriety: GSK: Not notable vs. JNJ: Notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GSK: 58% vs. JNJ: 107%
Market capitalization -- GSK: $88.13B vs. JNJ: $380.22B
GSK [@Pharmaceuticals: Major] is valued at $88.13B. JNJ’s [@Pharmaceuticals: Major] market capitalization is $380.22B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GSK’s FA Score shows that 2 FA rating(s) are green whileJNJ’s FA Score has 4 green FA rating(s).

  • GSK’s FA Score: 2 green, 3 red.
  • JNJ’s FA Score: 4 green, 1 red.
According to our system of comparison, JNJ is a better buy in the long-term than GSK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GSK’s TA Score shows that 4 TA indicator(s) are bullish while JNJ’s TA Score has 7 bullish TA indicator(s).

  • GSK’s TA Score: 4 bullish, 6 bearish.
  • JNJ’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, JNJ is a better buy in the short-term than GSK.

Price Growth

GSK (@Pharmaceuticals: Major) experienced а -5.70% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +1.99% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.63%. For the same industry, the average monthly price growth was +7.79%, and the average quarterly price growth was +14.77%.

Reported Earning Dates

GSK is expected to report earnings on Oct 29, 2025.

JNJ is expected to report earnings on Oct 21, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.63% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JNJ($380B) has a higher market cap than GSK($88.1B). JNJ has higher P/E ratio than GSK: JNJ (30.34) vs GSK (14.01). JNJ YTD gains are higher at: 19.921 vs. GSK (11.123). JNJ has higher annual earnings (EBITDA): 23.3B vs. GSK (9.08B). JNJ has more cash in the bank: 22.9B vs. GSK (4.99B). GSK has less debt than JNJ: GSK (18B) vs JNJ (29.3B). JNJ has higher revenues than GSK: JNJ (85.2B) vs GSK (30.3B).
GSKJNJGSK / JNJ
Capitalization88.1B380B23%
EBITDA9.08B23.3B39%
Gain YTD11.12319.92156%
P/E Ratio14.0130.3446%
Revenue30.3B85.2B36%
Total Cash4.99B22.9B22%
Total Debt18B29.3B61%
FUNDAMENTALS RATINGS
GSK vs JNJ: Fundamental Ratings
GSK
JNJ
OUTLOOK RATING
1..100
7374
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
21
Undervalued
PROFIT vs RISK RATING
1..100
7429
SMR RATING
1..100
4032
PRICE GROWTH RATING
1..100
5725
P/E GROWTH RATING
1..100
2881
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (9) in the Pharmaceuticals Major industry is in the same range as JNJ (21). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.

JNJ's Profit vs Risk Rating (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (74). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.

JNJ's SMR Rating (32) in the Pharmaceuticals Major industry is in the same range as GSK (40). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.

JNJ's Price Growth Rating (25) in the Pharmaceuticals Major industry is in the same range as GSK (57). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.

GSK's P/E Growth Rating (28) in the Pharmaceuticals Major industry is somewhat better than the same rating for JNJ (81). This means that GSK’s stock grew somewhat faster than JNJ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GSKJNJ
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
43%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
43%
Bearish Trend 2 days ago
44%
Momentum
ODDS (%)
Bearish Trend 2 days ago
46%
Bullish Trend 7 days ago
49%
MACD
ODDS (%)
Bearish Trend 2 days ago
42%
Bullish Trend 7 days ago
49%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
40%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
51%
Bullish Trend 2 days ago
40%
Advances
ODDS (%)
Bullish Trend 4 days ago
58%
Bullish Trend 4 days ago
41%
Declines
ODDS (%)
Bearish Trend 2 days ago
54%
Bearish Trend 2 days ago
43%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
48%
Aroon
ODDS (%)
Bearish Trend 2 days ago
39%
Bullish Trend 2 days ago
42%
View a ticker or compare two or three
Interact to see
Advertisement
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IWP141.050.47
+0.33%
iShares Russell Mid-Cap Growth ETF
MYI10.530.03
+0.29%
Blackrock Muniyield Quality Fund III
BLUBF5.58N/A
N/A
Blue Ribbon Income Fund
SMLV124.14-0.04
-0.03%
SPDR® SSGA US Small Cap Low Volatil ETF
PXI42.31-0.23
-0.53%
Invesco Dorsey Wright Energy MomentumETF

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been closely correlated with NVS. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
-1.53%
NVS - GSK
67%
Closely correlated
-3.59%
AZN - GSK
63%
Loosely correlated
-1.18%
PFE - GSK
58%
Loosely correlated
-3.31%
SNY - GSK
53%
Loosely correlated
-3.47%
AMGN - GSK
51%
Loosely correlated
-5.14%
More